Inhibrx Biosciences (INBX) Operating Income (2023 - 2026)

Inhibrx Biosciences (INBX) has reported Operating Income for 3 consecutive years, with -$30.9 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Operating Income rose 38.06% year-over-year to -$30.9 million; the TTM figure through Dec 2025 stood at -$135.0 million (up 59.26% YoY), while the FY2025 annual figure was -$135.0 million, up 59.26% from the prior year.
• Operating Income advanced to -$30.9 million in Q4 2025 per INBX's latest filing, from -$33.8 million in the prior quarter.
• Across five years, Operating Income topped out at -$27.4 million in Q2 2025 and bottomed at -$160.9 million in Q2 2024.
• Historically, Operating Income has averaged -$58.4 million across 3 years, with a median of -$45.8 million in 2023.
• Annual changes were most pronounced in 2024 — Operating Income plunged 289.22% — and 2025, when it jumped 82.98%.
• Inhibrx Biosciences' Operating Income stood at -$88.3 million in 2023, then jumped by 43.45% to -$49.9 million in 2024, then surged by 38.06% to -$30.9 million in 2025.
• Business Quant data shows INBX's Operating Income at -$30.9 million in Q4 2025, -$33.8 million in Q3 2025, and -$27.4 million in Q2 2025.